AR066265A1 - Compuestos y metodos para mejorar la solubilidad de florfenicol y antibioticos estructuralmente relacionados por medio del uso de ciclodextrinas. composicion. complejo. kit. metodo de tratamiento. - Google Patents
Compuestos y metodos para mejorar la solubilidad de florfenicol y antibioticos estructuralmente relacionados por medio del uso de ciclodextrinas. composicion. complejo. kit. metodo de tratamiento.Info
- Publication number
- AR066265A1 AR066265A1 ARP080101709A ARP080101709A AR066265A1 AR 066265 A1 AR066265 A1 AR 066265A1 AR P080101709 A ARP080101709 A AR P080101709A AR P080101709 A ARP080101709 A AR P080101709A AR 066265 A1 AR066265 A1 AR 066265A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- florfenicol
- water
- cyclodextrin
- complex
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Reivindicacion 1. Una composicion que comprende: a) de aproximadamente 2,5 a aproximadamente 35% en peso de florfenicol o una sal farmacéuticamente aceptable del mismo; b) de aproximadamente 0,5 a aproximadamente 20% en peso de una ciclodextrina; yc) de aproximadamente 20 a aproximadamente 95% en peso de agua, un solvente y/o una mezcla de los mismos. Reivindicacion 4. La composicion de la reivindicacion 1, donde la ciclodextrina es una ciclodextrina natural, una ciclodextrina modificada, ouna mezcla de las mismas. Reivindicacion 11. La composicion de la reivindicacion 1, donde el solvente se selecciona del grupo que consiste de polietilen glicol 300, polietilen glicol 400, propilen glicol, 2-pirol, n-metil pirol y mezclas de losmismos. Reivindicacion 15. Un método para tratar o prevenir una enfermedad, que comprende: introducir la composicion de la reivindicacion 1 directamente en el agua o en el agua a través de un sistema de tanque de mezcla con dosificador: yadministrar a un sujeto que lo necesita una cantidad terapéuticamente efectiva de un producto que resulta de la introduccion de la composicion en el agua. Reivindicacion 17. Un kit para tratar o prevenir una enfermedad en un sujeto, que comprendela composicion de la reivindicacion 1 e instrucciones para introducir la composicion en el agua para beber que se proporciona al sujeto. Reivindicacion 18. Un complejo de florfenicol que comprende una combinacion intima de florfenicol yciclodextrina preparada al formarse la composicion de la reivindicacion 1 y eliminar el agua, solvente y/o una mezcla de los mismos para formar el complejo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91437607P | 2007-04-27 | 2007-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066265A1 true AR066265A1 (es) | 2009-08-05 |
Family
ID=39619330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101709A AR066265A1 (es) | 2007-04-27 | 2008-04-23 | Compuestos y metodos para mejorar la solubilidad de florfenicol y antibioticos estructuralmente relacionados por medio del uso de ciclodextrinas. composicion. complejo. kit. metodo de tratamiento. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090062397A1 (es) |
EP (1) | EP2150245A1 (es) |
JP (1) | JP2010525059A (es) |
KR (1) | KR20100028537A (es) |
CN (1) | CN101686956A (es) |
AR (1) | AR066265A1 (es) |
BR (1) | BRPI0810601A2 (es) |
CA (1) | CA2685264A1 (es) |
CL (1) | CL2008001194A1 (es) |
MX (1) | MX2009011642A (es) |
PE (1) | PE20090234A1 (es) |
RU (1) | RU2009143731A (es) |
TW (1) | TW200908955A (es) |
WO (1) | WO2008133901A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20050386A1 (es) | 2003-05-29 | 2005-06-23 | Schering Plough Ltd | Composiciones farmaceuticas de florfenicol |
CA2672795A1 (en) * | 2006-12-13 | 2008-06-26 | Schering-Plough Ltd. | Water-soluble prodrugs of chloramphenicol, thiamphenicol, and analogs thereof |
GB2451811A (en) * | 2007-08-09 | 2009-02-18 | Ems Sa | Delivery composition for solubilising water-insoluble pharmaceutical active ingredients |
JP2011529895A (ja) * | 2008-07-30 | 2011-12-15 | インターベツト・インターナシヨナル・ベー・ベー | フロルフェニコール中間体として有用なオキサゾリン保護アミノジオール化合物を調製する方法 |
JP5826473B2 (ja) * | 2010-09-16 | 2015-12-02 | 協和発酵バイオ株式会社 | 直打用高単位グルコサミン顆粒 |
CN102160854A (zh) * | 2011-04-15 | 2011-08-24 | 广东养宝生物制药有限公司 | 一种包合环糊精的氟苯尼考速释型水溶性粉末制剂及其制备方法 |
CN102688197A (zh) * | 2012-06-07 | 2012-09-26 | 湖州爱宝莱动物药业有限公司 | 一种氟苯尼考水溶颗粒及其制备方法 |
CN102813627A (zh) * | 2012-09-19 | 2012-12-12 | 上海同仁药业有限公司 | 一种氟苯尼考可溶性粉剂的制备方法 |
CN104667291A (zh) * | 2013-12-03 | 2015-06-03 | 中牧实业股份有限公司黄冈动物药品厂 | 一种改进的氟苯尼考包合物的制备方法 |
CN104800167B (zh) * | 2015-04-22 | 2018-04-10 | 河南牧翔动物药业有限公司 | 一种氟苯尼考可溶性粉及其制备方法 |
CN105055319B (zh) * | 2015-07-22 | 2018-04-10 | 浙江大飞龙动物保健品有限公司 | 一种氟苯尼考可溶性粉及其制备方法 |
CN105079818B (zh) * | 2015-08-31 | 2018-04-20 | 王玉万 | 用乙酰胺和环糊精制备氟苯尼考可溶性粉 |
CN105477642B (zh) * | 2015-12-15 | 2019-08-06 | 中牧南京动物药业有限公司 | 一种高生物利用度的氟苯尼考组合物及其制备方法 |
CN106177983A (zh) * | 2016-08-03 | 2016-12-07 | 佛山科学技术学院 | 一种氟苯尼考‑β‑环糊精包合物及其制备方法 |
CN107519135A (zh) * | 2017-09-30 | 2017-12-29 | 中牧实业股份有限公司黄冈动物药品厂 | 一种高水溶型氟苯尼考粉的制备方法 |
CN109602916A (zh) * | 2018-12-13 | 2019-04-12 | 广东温氏大华农生物科技有限公司 | 一种氟苯尼考包合物及其制备方法 |
CN111374949A (zh) * | 2018-12-29 | 2020-07-07 | 西安市昌盛动物保健品有限公司 | 一种氟苯尼考可溶性粉或溶液的制备工艺 |
CN110279664B (zh) * | 2019-07-30 | 2021-09-03 | 四川农业大学 | 一种氟苯尼考包合物冻干粉针剂及其制备方法 |
CN112535663A (zh) * | 2019-09-23 | 2021-03-23 | 江西邦诚动物药业有限公司 | 一种速溶固体分散氟苯尼考粉及其制备方法 |
CN110787131B (zh) * | 2019-12-13 | 2022-04-01 | 河北远征药业有限公司 | 一种氟苯尼考可溶性粉制剂的制备方法 |
CN112190551A (zh) * | 2020-11-20 | 2021-01-08 | 湖北龙翔药业科技股份有限公司 | 一种氟苯尼考可溶性粉及其制备方法 |
CN112675315A (zh) * | 2021-01-05 | 2021-04-20 | 佛山科学技术学院 | 一种γ-环糊精-替米考星包合物及其制备方法和应用 |
CN112716902B (zh) * | 2021-02-04 | 2021-10-12 | 广州市和生堂动物药业有限公司 | 一种氟苯尼考粉及其制备方法 |
CN112641730A (zh) * | 2021-02-19 | 2021-04-13 | 山东鲁抗舍里乐药业有限公司高新区分公司 | 一种可溶氟苯尼考粉的制备方法 |
CN113230233A (zh) * | 2021-05-14 | 2021-08-10 | 中国农业科学院兰州畜牧与兽药研究所 | 一种氟苯尼考固体分散包合微囊及其制备方法与应用 |
CN114272213B (zh) * | 2021-12-28 | 2023-10-10 | 厦门惠盈动物药业有限公司 | 一种氟苯尼考粉及其制备方法 |
CN114209656B (zh) * | 2021-12-31 | 2023-08-01 | 浙江金朗博药业有限公司 | 一种氟苯尼考可溶性粉及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8104203A1 (es) * | 1979-02-05 | 1981-04-16 | Schering Corp | Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol |
IT1173213B (it) * | 1984-02-03 | 1987-06-18 | Zambon Spa | Procedimento per fluorurare alcuni derivati dall'1l-fenil-2-ammino-1,3-propandiolo e loro intermedi |
US5105009A (en) * | 1983-06-02 | 1992-04-14 | Zambon S.P.A. | Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoropropane derivatives |
US5332835A (en) * | 1984-02-03 | 1994-07-26 | Zambon S.P.A. | Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process |
US4582918A (en) * | 1984-09-19 | 1986-04-15 | Schering Corporation | Preparation of intermediates for (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols |
US4973750A (en) * | 1984-09-19 | 1990-11-27 | Schering Corporation | Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols |
US5227494A (en) * | 1988-09-14 | 1993-07-13 | Schering Corporation | Process for preparing oxazoline compounds |
US4876352A (en) * | 1988-09-14 | 1989-10-24 | Schering Corporation | Pressurized fluorination of hydroxy alkyl groups |
DE69102900T3 (de) * | 1990-02-14 | 1998-04-09 | Takeda Chemical Industries Ltd | Brausemischung, deren Herstellung sowie Verwendung. |
HU212617B (en) * | 1990-10-25 | 1996-09-30 | Schering Corp | Process for preparating florfenicol and its analogs thereto |
US5352832A (en) * | 1992-12-18 | 1994-10-04 | Schering Corporation | Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates |
US5663361A (en) * | 1996-08-19 | 1997-09-02 | Schering Corporation | Process for preparing intermediates to florfenicol |
GB0205253D0 (en) * | 2002-03-06 | 2002-04-17 | Univ Gent | Immediate release pharmaceutical granule compositions and a continuous process for making them |
US6790867B2 (en) * | 2002-05-20 | 2004-09-14 | Schering-Plough Animal Health Corporation | Compositions and method for treating infection in cattle and swine |
CN1459282A (zh) * | 2003-05-29 | 2003-12-03 | 季华 | 水溶性氟苯尼考的生产方法 |
-
2008
- 2008-04-23 PE PE2008000695A patent/PE20090234A1/es not_active Application Discontinuation
- 2008-04-23 EP EP08743209A patent/EP2150245A1/en not_active Withdrawn
- 2008-04-23 BR BRPI0810601-0A2A patent/BRPI0810601A2/pt not_active IP Right Cessation
- 2008-04-23 CA CA002685264A patent/CA2685264A1/en not_active Abandoned
- 2008-04-23 WO PCT/US2008/005225 patent/WO2008133901A1/en active Application Filing
- 2008-04-23 JP JP2010506241A patent/JP2010525059A/ja not_active Withdrawn
- 2008-04-23 US US12/108,032 patent/US20090062397A1/en not_active Abandoned
- 2008-04-23 RU RU2009143731/15A patent/RU2009143731A/ru not_active Application Discontinuation
- 2008-04-23 CN CN200880021603A patent/CN101686956A/zh active Pending
- 2008-04-23 MX MX2009011642A patent/MX2009011642A/es not_active Application Discontinuation
- 2008-04-23 KR KR1020097024467A patent/KR20100028537A/ko not_active Application Discontinuation
- 2008-04-23 AR ARP080101709A patent/AR066265A1/es unknown
- 2008-04-24 TW TW097115132A patent/TW200908955A/zh unknown
- 2008-04-24 CL CL2008001194A patent/CL2008001194A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010525059A (ja) | 2010-07-22 |
EP2150245A1 (en) | 2010-02-10 |
US20090062397A1 (en) | 2009-03-05 |
CL2008001194A1 (es) | 2008-11-03 |
CN101686956A (zh) | 2010-03-31 |
RU2009143731A (ru) | 2011-06-10 |
BRPI0810601A2 (pt) | 2014-10-21 |
WO2008133901A1 (en) | 2008-11-06 |
MX2009011642A (es) | 2010-01-29 |
KR20100028537A (ko) | 2010-03-12 |
CA2685264A1 (en) | 2008-11-06 |
PE20090234A1 (es) | 2009-04-02 |
TW200908955A (en) | 2009-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066265A1 (es) | Compuestos y metodos para mejorar la solubilidad de florfenicol y antibioticos estructuralmente relacionados por medio del uso de ciclodextrinas. composicion. complejo. kit. metodo de tratamiento. | |
JP2010525059A5 (es) | ||
CL2019002167A1 (es) | Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.) | |
Thomas et al. | An in vitro spectroscopic analysis to determine whether para-chloroaniline is produced from mixing sodium hypochlorite and chlorhexidine | |
AR069830A1 (es) | Factor viii y factor de von willebrand recombinantes modificados y metodos de uso de los mismos | |
AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
CA2716874A1 (en) | A pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases | |
CL2020003131A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
BRPI0710485B1 (pt) | composições líquidas úteis no tratamento de doenças respiratórias | |
AR026122A1 (es) | Derivados de 3(5)-amino-pirazol, procedimiento para su preparacion y su uso como agente antitumorales | |
AR073361A1 (es) | Combinacion farmaceutica que comprende 3-(-3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico. uso | |
UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
ECSP13012964A (es) | Tratamientos combinados para neoplasias hematologicas malignas | |
BRPI0408256A (pt) | composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo | |
AR057099A1 (es) | Una forma cristalina, un proceso de preparacion y composicion farmaceutica | |
CL2004000918A1 (es) | Compuestos derivados de quinuclidina, antagonistas del receptor muscarinico m3; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para tratar una condicion anti-inflamatoria o alergica, en particular de las vias respiratoria | |
SI2945620T1 (en) | Nitroxyl donors with improved therapeutic index | |
AR117718A2 (es) | Mejoramientos en composiciones farmacéuticas, y relacionados con ellas | |
BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
BR112017017211A2 (pt) | composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto. | |
CL2010001488A1 (es) | Proceso para preparar 2,4-dioxo-1,2,4-tetrahidropirido[2,3-d]pirimidin-7-il-fenil sustituido y 2,4-bis[3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-7-il-fenil-sustituido; sal fumarato de {5-[2,4-bis[(3s)-3-metilmorfolin-4-il]pirido[2,3-d]pirimidin-7-il]-2-metoxifenil}metanol; composicon farmaceutica; y uso para tratar el cancer. | |
PE20120788A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |